Your browser is no longer supported. Please, upgrade your browser.
VIVO [NASD]
Meridian Bioscience, Inc.
Index- P/E19.74 EPS (ttm)1.07 Insider Own1.30% Shs Outstand42.96M Perf Week-12.31%
Market Cap1.01B Forward P/E15.97 EPS next Y1.32 Insider Trans-21.39% Shs Float42.87M Perf Month-1.31%
Income46.20M PEG1.16 EPS next Q0.50 Inst Own95.80% Short Float7.65% Perf Quarter21.71%
Sales253.70M P/S4.00 EPS this Y88.20% Inst Trans3.47% Short Ratio4.71 Perf Half Y33.76%
Book/sh5.76 P/B3.66 EPS next Y-26.05% ROA11.80% Target Price35.00 Perf Year158.33%
Cash/sh1.11 P/C18.95 EPS next 5Y17.00% ROE19.80% 52W Range5.51 - 30.65 Perf YTD12.79%
Dividend- P/FCF27.93 EPS past 5Y4.80% ROI15.20% 52W High-31.22% Beta0.60
Dividend %- Quick Ratio1.90 Sales past 5Y5.40% Gross Margin61.60% 52W Low282.58% ATR1.81
Employees560 Current Ratio3.10 Sales Q/Q26.40% Oper. Margin22.70% RSI (14)39.79 Volatility6.56% 8.03%
OptionableYes Debt/Eq0.00 EPS Q/Q55.70% Profit Margin17.30% Rel Volume0.88 Prev Close21.71
ShortableYes LT Debt/Eq0.28 EarningsFeb 05 BMO Payout0.00% Avg Volume695.64K Price21.08
Recom1.50 SMA20-15.96% SMA50-7.12% SMA2007.84% Volume608,929 Change-2.90%
Aug-11-20Resumed Piper Sandler Overweight $24
Jul-27-20Initiated H.C. Wainwright Buy $34
May-11-20Upgrade William Blair Mkt Perform → Outperform
May-01-19Upgrade Piper Jaffray Underweight → Neutral $15 → $11
Apr-03-19Downgrade Canaccord Genuity Hold → Sell $17 → $11
Jan-26-18Reiterated Canaccord Genuity Hold $14 → $16
Mar-28-17Initiated CL King Neutral
Mar-28-16Reiterated Canaccord Genuity Hold $18 → $19
Sep-10-15Reiterated Canaccord Genuity Hold $19 → $18
Jul-27-15Reiterated Canaccord Genuity Hold $20 → $19
May-04-15Reiterated Canaccord Genuity Hold $19 → $20
Nov-06-14Downgrade Robert W. Baird Outperform → Neutral $22 → $22
Jul-27-12Downgrade Canaccord Genuity Buy → Hold
Apr-25-11Upgrade Wedbush Underperform → Neutral $18 → $22
Mar-24-11Upgrade Canaccord Genuity Hold → Buy $30
Nov-16-10Initiated Canaccord Genuity Hold $21
Apr-07-10Initiated Wedbush Underperform $18
Nov-13-09Reiterated Caris & Company Average $21 → $20
Jul-07-09Initiated Caris & Company Average $21
Mar-06-09Initiated William Blair Mkt Perform
Feb-23-21 02:30PM  
01:47PM  
01:16PM  
08:00AM  
Feb-22-21 01:06PM  
Feb-20-21 07:00PM  
Feb-18-21 09:47PM  
04:35PM  
Feb-16-21 08:00AM  
Feb-12-21 12:45PM  
11:16AM  
09:28AM  
Feb-11-21 04:15PM  
09:01AM  
08:27AM  
05:40AM  
05:20AM  
Feb-10-21 09:26AM  
09:14AM  
Feb-09-21 09:56AM  
09:41AM  
Feb-08-21 11:30AM  
Feb-05-21 02:01PM  
08:45AM  
08:15AM  
07:47AM  
07:30AM  
Feb-04-21 08:40AM  
Feb-03-21 10:30AM  
Feb-02-21 09:41AM  
08:00AM  
Jan-29-21 05:50PM  
09:59AM  
Jan-28-21 08:02AM  
Jan-27-21 10:42AM  
Jan-21-21 05:50PM  
Jan-20-21 12:10PM  
Jan-19-21 09:56AM  
Jan-14-21 05:50PM  
Jan-13-21 04:30PM  
Jan-12-21 08:03AM  
Jan-11-21 07:09AM  
Jan-08-21 11:12AM  
09:12AM  
06:48AM  
05:54AM  
05:20AM  
Jan-07-21 08:19AM  
08:00AM  
Jan-06-21 09:30AM  
Jan-05-21 12:20PM  
Dec-31-20 11:30AM  
Dec-29-20 03:31PM  
06:55AM  
Dec-28-20 07:59AM  
Dec-18-20 01:12AM  
Dec-17-20 10:28AM  
Dec-16-20 03:00PM  
Dec-14-20 10:34AM  
07:19AM  
Dec-11-20 07:58AM  
Dec-09-20 11:30AM  
Dec-08-20 10:17AM  
Dec-03-20 12:20PM  
10:00AM  
Nov-23-20 10:00AM  
Nov-20-20 08:35AM  
Nov-18-20 11:25AM  
Nov-17-20 11:30AM  
Nov-16-20 12:00PM  
05:55AM  
Nov-13-20 01:30PM  
10:10AM  
07:30AM  
Nov-06-20 12:30PM  
Oct-26-20 01:50PM  
Oct-21-20 01:44PM  
Oct-20-20 11:00AM  
Oct-16-20 01:38PM  
Oct-07-20 09:00AM  
Oct-06-20 10:23PM  
Sep-17-20 03:17PM  
Sep-14-20 10:00AM  
Aug-31-20 08:00AM  
Aug-25-20 09:31AM  
Aug-07-20 09:05AM  
08:52AM  
07:30AM  
Aug-06-20 04:00PM  
Aug-05-20 09:42AM  
Jul-31-20 05:45PM  
12:30PM  
Jul-28-20 10:24AM  
09:00AM  
Jul-27-20 09:33AM  
Jul-16-20 09:00AM  
Jul-13-20 01:57PM  
01:00PM  
Jul-10-20 11:30AM  
Jul-01-20 09:37AM  
Meridian Bioscience, Inc., a life science company, develops, manufactures, distributes, and sells diagnostic test kits primarily for gastrointestinal and respiratory infectious diseases, and elevated blood lead levels worldwide. The company operates through Diagnostics and Life Science segments. The Diagnostics segment offers testing platforms, including real-time PCR amplification under the Revogene brand; isothermal DNA amplification under the Alethia brand; lateral flow immunoassay using fluorescent chemistry under the Curian brand; rapid immunoassay under the ImmunoCard and ImmunoCard STAT! brands; enzyme-linked immunoassays under the PREMIER brand; anodic stripping voltammetry under the LeadCare and PediaStat brands; and urea breath testing for H. pylori under the BreathID brand. This segment also offers gastrointestinal assays, including tests for C. difficile, H. pylori, and certain foodborne pathogens; respiratory illness assays, such as tests Group A strep, mycoplasma pneumonia, influenza, and pertussis; and blood chemistry assays for testing elevated levels of lead in blood. It sells products through direct sales force and independent distributors to acute care hospitals, reference laboratories, outpatient clinics, and physician office laboratories. The Life Science segment offers bulk antigens, antibodies, PCR/qPCR reagents, nucleotides, and bioresearch reagents used by in vitro diagnostic manufacturers, as well as researchers in immunological and molecular tests for human, animal, plant, and environmental applications. The company has a strategic collaboration with DiaSorin Inc. to sell H. pylori tests. Meridian Bioscience, Inc. was incorporated in 1976 and is headquartered in Cincinnati, Ohio.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Kenny John P.Chief Executive OfficerFeb 16Option Exercise10.102,08221,028251,018Feb 17 10:14 AM
Kenny John P.Chief Executive OfficerFeb 16Sale30.352,35971,604248,659Feb 17 10:14 AM
Kenny John P.Chief Executive OfficerFeb 12Option Exercise10.1023,097233,280275,117Feb 16 08:45 AM
Kenny John P.Chief Executive OfficerFeb 12Sale30.1426,181789,085248,936Feb 16 08:45 AM
Kenny John P.Chief Executive OfficerFeb 11Option Exercise10.101,16411,756253,340Feb 16 08:45 AM
Kenny John P.Chief Executive OfficerFeb 11Sale30.001,32039,601252,020Feb 16 08:45 AM
Rice John McCune Jr.DirectorFeb 08Option Exercise11.6027,205315,46440,917Feb 09 03:02 PM
Baldasare Bryan TExec VP & CFOFeb 08Option Exercise19.563,75073,35062,382Feb 09 01:26 PM
Kenny John P.Chief Executive OfficerFeb 08Option Exercise13.4366,134887,953320,464Feb 10 01:22 PM
Kenny John P.Chief Executive OfficerFeb 08Sale29.8668,2882,039,114252,176Feb 10 01:22 PM
Baldasare Bryan TExec VP & CFOFeb 08Sale30.006,254187,62056,128Feb 09 01:26 PM
Rice John McCune Jr.DirectorFeb 08Sale28.1616,480464,00824,437Feb 09 03:02 PM
Baldasare Bryan TExec VP & CFOFeb 05Option Exercise19.5611,250220,05072,882Feb 08 10:21 AM
Baldasare Bryan TExec VP & CFOFeb 05Sale26.6114,250379,12658,632Feb 08 10:21 AM
Kenny John P.Chief Executive OfficerFeb 05Sale25.0040,0001,000,000254,330Feb 08 10:18 AM
Bihl Anthony P IIIDirectorNov 25Buy17.655,00088,26610,851Nov 30 10:47 AM
Baldasare Bryan TExec VP & CFOJun 30Option Exercise19.711,50029,56554,137Jul 02 01:52 PM
Williams FeliciaDirectorMar 16Buy6.021,5509,3315,717Mar 17 01:55 PM
Kenny John P.Chief Executive OfficerMar 12Buy5.7830,000173,541238,324Mar 13 09:05 AM
Baldasare Bryan TExec VP & CFOMar 10Buy6.972,00013,93652,637Mar 11 01:47 PM